Wallac Oy, A Subsidiary of Perkinelmer

Wallac Oy, A Subsidiary of Perkinelmer — FDA 510(k) Submissions

Wallac Oy, A Subsidiary of Perkinelmer has submitted 1 FDA 510(k) premarket notifications since 2018, of which 1 received clearance as substantially equivalent to a predicate device.

The company's most frequent device categories include Alpha-d-galactosidase A (gla) Newborn Screening Test System . Use the specialty filter in the sidebar to narrow results.